IP Verse

Polymorphic And Pseudopolymorphic Forms Of Pharmaceutical Compound Nxl104 - EP3269717B9

PatentPatent Analysis

EP3269717

PFIZER IRELAND PHARMACEUTICALS
Application Number
EP17182561A
Filing Date
Oct 8, 2010
Status
Patent Maintained As Amended
May 12, 2023
Grant Date
Aug 9, 2023
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2357250B1
EP1789571B1

Bibliography

The patent EP3269717B9 was granted to Pfizer Ireland Pharmaceuticals on Aug 9, 2023 following the initial filing on Oct 8, 2010 under the application number EP17182561A . The current legal status of the patent is Patent Maintained As Amended.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBNov 26, 2019ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents